---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-252990"
form_type: "8-K"
ticker: null
cik: "0001661460"
company_name: "Poseida Therapeutics, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:29:21.365492+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Poseida announces CEO transition; Kristin Yarema to become CEO, Mark Gergen to become Executive Chairman

## Summary
- Kristin Yarema, currently President, Cell Therapy, appointed President and CEO effective January 1, 2024.
- Mark Gergen, current President and CEO, will become Executive Chairman of the Board on the same date.
- Amended employment agreements to be entered with Dr. Yarema and Mr. Gergen prior to effective date.
- No material transactions or family relationships disclosed between Dr. Yarema and the company.

## SEC filing metadata
- accession: 0001193125-23-252990
- form_type: 8-K
- cik: 0001661460
- company_name: Poseida Therapeutics, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/d472927d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-252990
- JSON: https://secwatch.observer/filing/0001193125-23-252990.json
- Plain text: https://secwatch.observer/filing/0001193125-23-252990.txt

## Key facts
- Executive change
  Mark Gergen was appointed as Executive Chairman at Poseida Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: The Board also appointed Mark Gergen, the Company’s current President and Chief Executive Officer, as Executive Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm
- Executive change
  Kristin Yarema was appointed as President and Chief Executive Officer at Poseida Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: approved a leadership transition appointing Kristin Yarema, Ph.D., as President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.